Recently added Catalysts

RADX Positive Sentiment Score: 70/100

Investor Presentation

Wednesday, January 24, 2024 1 min read

Key Takeaway: Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). This follows the company's recent IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared regarding four of their clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
The company received IND approval from the US FDA.
Positive clinical updates were provided across four programs.

Full Press Release Details

• Announcements

• January 24, 2024

Loading Viewer…

More Announcements & Updates

• Announcements

• October 31, 2022

• Updates

• December 14, 2023

• Announcements

• October 31, 2023

• Announcements

• February 6, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026

• Zacks Small-Cap Research 2026

• RAD Presentation March 2026

• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of the Phase 1/2a study?

The Phase 1/2a study focuses on BetaBart (RV-01) targeting B7H3.

When was the first patient dosed?

The first patient was dosed in January 2024.

What recent approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA.

How many clinical programs received positive updates?

Positive updates were provided across four clinical programs.